Abstract:Tetrahydroprotoberberines (THPBs), a class of naturally occurring isoquinoline alkaloids, contain substituent methoxyl or hydroxyl groups which play a significant role in the pharmacological properties of these molecules. In this study, we report a biocatalytic strategy for selective O-demethylation of THPBs. CYP105D1, a cytochrome P450 from Streptomyces griseus ATCC 13273, exhibited markedly regioselective demethylation of nonhydroxyl-THPBs and monohydroxyl-THPBs on the D-ring. A possible binding mode of THPBs with CYP105D1 was investigated by docking analysis, and the results revealed that the D-rings of THPBs were with the minimum distance to the heme iron. Tetrahydropalmatine was used as a model substrate and enantioselective demethylation was demonstrated. (S)-Tetrahydropalmatine was only demethylated at C-10, while (R)-tetrahydropalmatine was first demethylated at C-10 and then subsequently demethylated at C-9. The kcat/Km value for demethylation of (R)-tetrahydropalmatine by CYP105D1 was 3.7 times greater than that for demethylation of (S)-tetrahydropalmatine. Furthermore, selective demethylation of (S)-tetrahydropalmatine by the CYP105D1-based whole-cell system was demonstrated for the highly efficient production of (S)-corydalmine which has distinct pharmacological applications, such as providing relief from bone cancer pain and reducing morphine tolerance. Moreover, a homologous redox partner was identified to enhance the catalytic efficiency of the CYP105D1-based whole-cell system. This is the first enzymatic characterization of a cytochrome P450 that has regio- and enantioselective demethylation activity of THPBs for application purpose. The cytochrome P450 system could be a promising strategy for selective demethylation in the pharmaceutical industry.

Design, Synthesis, and Pharmacological Evaluation of Novel Tetrahydroprotoberberine Derivatives: Selective Inhibitors of Dopamine D1 Receptor

Asymmetric Total Synthesis and Identification of Tetrahydroprotoberberine Derivatives As New Antipsychotic Agents Possessing a Dopamine D1, D2 and Serotonin 5-HT1A Multi-Action Profile

Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands.

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Synthesis, Preliminary Pharmacological Evaluation and Receptor Docking Studies of 10-Amino-3-methoxy-6,8,12,12a-tetrahydro-5h-thiazolo[4',5':4,5]Pyrido[2,1-a]isoquinolin-2-ols As Novel Dopamine D1 Receptor Inhibitors

Studies On Dopamine Receptors And Tetrahydroprotoberberines .3. 3d-Qsar Study On Tetrahydroprotoberberines Using Comfa Approach

Significantly Different Effects of Tetrahydroberberrubine Enantiomers on Dopamine D1/D2 Receptors Revealed by Experimental Study and Integrated in Silico Simulation

Design, Synthesis and Evaluation of Benzo[a]thieno[3,2-G]quinolizines As Novel L-Spd Derivatives Possessing Dopamine D1, D2 and Serotonin 5-HT1A Multiple Action Profiles.

Synthesis and Biological Investigation of Tetrahydropyridopyrimidinone Derivatives As Potential Multireceptor Atypical Antipsychotics.

[Antagonistic Effect of Tetrahydroproberberine Homologues on Alpha 1-Adrenoceptor].

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Drug Metabolism-Based Design, Synthesis, and Bioactivities of 1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane Hydrochloride (DDPH) Analogs As Α1-Adrenoceptors Antagonists

Design, Synthesis, and Biological Evaluation of Structurally Constrained Hybrid Analogues Containing Ropinirole Moiety As a Novel Class of Potent and Selective Dopamine D3 Receptor Ligands

Molecular insights into the D1R agonist and D2R/D3R antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations

Novel 1-(Prop-2-yn-1-ylamino)-2,3-dihydro-1h-indene-4-thiol Derivatives As Potent Selective Human Monoamine Oxidase B Inhibitors: Design, SAR Development, and Biological Evaluation.

Design, synthesis and biological evaluation of bitopic arylpiperazine-hexahydro-pyrazinoquinolines as preferential dopamine D3 receptor ligands

Design, Synthesis and Preliminary Bioactivity Evaluation of Bitopic Benzopyranomorpholine Analogues As Selective Dopamine D3 Receptor Ligands As Anti-Drug Addiction Therapeutic Agents

Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives to Reduce SREBPs Expression for the Treatment of Hyperlipidemia.

Discovery of Novel Bromophenol 3,4-Dibromo-5-(2-bromo-3,4-dihydroxy-6-(isobutoxymethyl)benzyl)benzene-1,2-diol As Protein Tyrosine Phosphatase 1B Inhibitor and Its Anti-Diabetic Properties in C57BL/KsJ-db/db Mice.

Synthesis and Evaluation of a Series of 2-Substituted-5-thiopropylpiperazine (Piperidine)-1,3,4-oxadiazoles Derivatives As Atypical Antipsychotics.

Regio- and Enantioselective O-demethylation of Tetrahydroprotoberberines by Cytochrome P450 Enzyme System from Streptomyces Griseus ATCC 13273